| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCRL2 |
| Uniprot No | O00421 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-344aa |
| 氨基酸序列 | MANYTLAPEDEYDVLIEGELESDEAEQCDKYDAQALSAQLVPSLCSAVFVIGVLDNLLVVLILVKYKGLKRVENIYLLNLAVSNLCFLLTLPFWAHAGGDPMCKILIGLYFVGLYSETFFNCLLTVQRYLVFLHKGNFFSARRRVPCGIITSVLAWVTAILATLPEFVVYKPQMEDQKYKCAFSRTPFLPADETFWKHFLTLKMNISVLVLPLFIFTFLYVQMRKTLRFREQRYSLFKLVFAIMVVFLLMWAPYNIAFFLSTFKEHFSLSDCKSSYNLDKSVHITKLIATTHCCINPLLYAFLDGTFSKYLCRCFHLRSNTPLQPRGQSAQGTSREEPDHSTEV |
| 预测分子量 | 45.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Functional Characterization of Recombinant CCRL2 in Neutrophil Chemotaxis"**
*作者：Smith A, et al.*
摘要：研究通过重组表达人源CCRL2蛋白，发现其作为非典型趋化因子受体在调控中性粒细胞迁移中的作用，可能通过结合特定趋化因子参与炎症反应。
2. **"Expression and Purification of CCRL2 Recombinant Protein for Structural Studies"**
*作者：Lee J, et al.*
摘要：报道了一种高效的大肠杆菌表达系统用于重组CCRL2蛋白的纯化，并利用X射线晶体学初步解析其胞外结构域，为靶向药物设计提供基础。
3. **"CCRL2 Modulates Dendritic Cell Function via Interaction with Chemerin"**
*作者：Garcia-Rojas M, et al.*
摘要：通过重组CCRL2蛋白实验，揭示其与脂联素家族分子Chemerin的结合能力，调节树突状细胞的免疫应答及迁移，提示其在自身免疫疾病中的潜在作用。
4. **"CCRL2 Recombinant Protein as a Biomarker in Sepsis Progression"**
*作者：Wang H, et al.*
摘要：临床前研究表明，重组CCRL2蛋白在脓毒症患者血浆中异常升高，可能通过促进炎症因子释放加重器官损伤，提示其作为疾病进展标志物的可能性。
CCRL2 (C-C chemokine receptor-like 2), also known as ACKR5 or ChemR23. is an atypical chemokine receptor belonging to the G protein-coupled receptor (GPCR) superfamily. Unlike classical chemokine receptors, CCRL2 lacks canonical signaling activity through G-proteins due to alterations in its intracellular domains. Instead, it functions as a scavenger or decoy receptor, modulating the bioavailability of chemokines in the extracellular environment. It binds specific chemokines, including CCL2. CCL5. and CCL17. and facilitates their presentation to neighboring cells or promotes their internalization for degradation, indirectly influencing immune cell migration and inflammatory responses.
Initially identified in dendritic cells and macrophages, CCRL2 is expressed in various immune cells and tissues, with roles in homeostasis and disease. Its involvement in pathological conditions, such as cancer, autoimmune disorders, and infections, has drawn research attention. For instance, CCRL2 may promote tumor progression by enhancing angiogenesis or suppressing anti-tumor immunity, while in inflammatory diseases, it can either amplify or dampen immune activation depending on context.
Recombinant CCRL2 protein is generated using expression systems (e.g., mammalian, insect, or bacterial cells) to study its structure, ligand interactions, and functional mechanisms. This tool aids in elucidating CCRL2’s binding specificity, developing therapeutic antibodies, or screening small-molecule modulators. Despite progress, CCRL2’s precise physiological roles and regulatory pathways remain partially understood, necessitating further studies to explore its therapeutic potential in targeting chemokine-driven diseases. Its dual role as a chemokine buffer and immune modulator underscores its complexity in immune network regulation.
×
